|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7052 | |
| A61K 31/00 | |||
| A61P 31/04 |
| (11) | Number of the document | 2068890 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07872765.8 |
| Date of filing the European patent application | 2007-09-24 | |
| (97) | Date of publication of the European application | 2009-06-17 |
| (45) | Date of publication and mention of the grant of the patent | 2014-01-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2007/079277 |
| Date | 2007-09-24 |
| (87) | Number | WO 2008/097364 |
| Date | 2008-08-14 |
| (30) | Number | Date | Country code |
| 847397 P | 2006-09-25 | US |
| (72) |
MOECK, Gregory, CA
PARR, Thomas, Reeves, Jr., US
|
| (73) |
The Medicines Company,
8 Sylvan Way, Parsippany, NJ 07054,
US
|
| (54) | USE OF ORITAVANCIN FOR PREVENTION AND TREATMENT OF ANTHRAX |
| USE OF ORITAVANCIN FOR PREVENTION AND TREATMENT OF ANTHRAX |